Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Shares Outstanding (Weighted Average) (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 6 years of Shares Outstanding (Weighted Average) data on record, last reported at $46.1 million in Q4 2020.

  • For Q4 2020, Shares Outstanding (Weighted Average) rose 51.05% year-over-year to $46.1 million; the TTM value through Dec 2020 reached $46.1 million, up 51.05%, while the annual FY2020 figure was $46.1 million, 51.05% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $46.1 million in Q4 2020 per SNDX's latest filing, up from $44.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $46.1 million in Q4 2020 and bottomed at $4.5 million in Q1 2016.
  • Average Shares Outstanding (Weighted Average) over 5 years is $26.1 million, with a median of $25.0 million recorded in 2018.
  • Peak YoY movement for Shares Outstanding (Weighted Average): soared 29620.87% in 2016, then grew 9.72% in 2017.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $14.6 million in 2016, then skyrocketed by 43.62% to $21.0 million in 2017, then rose by 20.83% to $25.4 million in 2018, then grew by 20.18% to $30.5 million in 2019, then soared by 51.05% to $46.1 million in 2020.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $46.1 million in Q4 2020, $44.2 million in Q3 2020, and $40.6 million in Q2 2020.